Normal view MARC view ISBD view

Conventional Radioiodine Therapy for Differentiated Thyroid Cancer. [Review]

MedStar author(s):

Citation: Endocrinology & Metabolism Clinics of North America. 48(1):181-197, 2019 03.PMID: 30717901Institution: MedStar Health Research Institute | MedStar Washington Hospital CenterDepartment: Medicine/Endocrinology | Medicine/Nuclear MedicineForm of publication: Journal ArticleMedline article type(s): Journal Article | ReviewSubject headings: *Iodine Radioisotopes/tu [Therapeutic Use] | *Thyroid Neoplasms/rt [Radiotherapy] | Humans | Iodine Radioisotopes/ad [Administration & Dosage]Year: 2019 Local holdings: Available online from MWHC library: 1996 - presentISSN:

0889-8529

Name of journal: Endocrinology and metabolism clinics of North AmericaAbstract: Copyright (c) 2018 Elsevier Inc. All rights reserved.This article presents an overview of the use of radioactive iodine (131-I) in the treatment of patients with differentiated thyroid cancer. Topics reviewed include definitions; staging; the 2 principal methods for selection of 131-I dosage; the indications for ablation, adjuvant treatment, and treatment; the recommendations for the use of 131-I contained in the guidelines of the American Thyroid Association and the Society of Nuclear Medicine and Molecular Imaging; the dosage recommendations and selection of dosage approach for 131-I by these organizations; the use of recombinant human thyrotropin for radioiodine ablation, adjuvant therapy, or treatment; and the MedStar Washington Hospital Center approach.All authors: Van Nostrand D, Wartofsky L, Ylli DFiscal year: FY2019Digital Object Identifier:

https://dx.doi.org/10.1016/j.ecl.2018.11.005

Date added to catalog: 2019-03-14

Holdings ( 1 )
Title notes ( 4 )

Holdings
Item type	Current library	Collection	Call number	Status	Date due	Barcode
Journal Article	MedStar Authors Catalog	Article	30717901	Available		30717901

Available online from MWHC library: 1996 - present

This article presents an overview of the use of radioactive iodine (131-I) in the treatment of patients with differentiated thyroid cancer. Topics reviewed include definitions; staging; the 2 principal methods for selection of 131-I dosage; the indications for ablation, adjuvant treatment, and treatment; the recommendations for the use of 131-I contained in the guidelines of the American Thyroid Association and the Society of Nuclear Medicine and Molecular Imaging; the dosage recommendations and selection of dosage approach for 131-I by these organizations; the use of recombinant human thyrotropin for radioiodine ablation, adjuvant therapy, or treatment; and the MedStar Washington Hospital Center approach.

English